Scrip Asks…What Does 2024 Hold For Biopharma? Part 4: Transformative Technology

“I’m optimistic when it comes to both the integration and the impact of transformative technologies across the life sciences industry,” said Jessica Federer, Bayer’s former chief digital officer and a board member and investor for companies in the health sector. “Incumbents, investors, and founders have learned from the over-promising and under-delivering first generation of digital and are investing and implementing with much more realistic expectations of results, and importantly, reimbursements. This translates into slower but more sustainable progress.”

Federer foresees tangible results from the use of technology across the spectrum of companies’ activities. “We can expect to see a broader adoption of technologies delivering more meaningful results for operational efficiency, manufacturing, drug discovery and development, regulatory, market access and commercial success